Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
O60930

UPID:
RNH1_HUMAN

ALTERNATIVE NAMES:
Ribonuclease H type II

ALTERNATIVE UPACC:
O60930; B3KQU4; O60523; O60857; Q57Z93; Q5U0C1; Q6FHD4

BACKGROUND:
Ribonuclease H1, alternatively named Ribonuclease H type II, is essential for degrading RNA-DNA hybrids, thus playing a key role in RNA polymerase II transcription termination. This enzyme's function is critical for preventing the accumulation of R-loop RNA-DNA hybrids, which can lead to genomic instability if not properly managed.

THERAPEUTIC SIGNIFICANCE:
Linked to a form of progressive external ophthalmoplegia, Ribonuclease H1's dysfunction highlights its importance in mitochondrial health and function. The exploration of Ribonuclease H1's mechanisms offers promising avenues for developing treatments for mitochondrial disorders, emphasizing the therapeutic potential of targeting this protein.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.